Navigating complexity in early-stage healthcare investing.
In my professional life, I have worked in pharmaceutical R&D across discovery, development, and translational science, leading programs spanning biologics and small molecules across therapeutic areas.
Alongside my professional work, I have worked closely with startup founders as a mentor and angel investor, supporting emerging companies in therapeutics, medical devices, and digital health.
A Science-Driven Perspective on Early-Stage Healthcare Innovation
I started ChaosBio as a platform to share my perspective on healthcare innovation, early-stage investing, and the complexity of translating scientific ideas into healthcare impact.
My background in pharmaceutical R&D provided firsthand exposure to the scientific, operational, and translational challenges involved in advancing new therapeutics from scientific concept toward clinical development.
In recent years, I have become increasingly involved in the healthcare startup ecosystem through founder mentorship and angel investing across therapeutics, medical devices, and digital health. I am particularly interested in companies operating at the intersection of strong science, clear clinical need, and thoughtful execution.
Through ChaosBio, I aim to support founders building meaningful healthcare innovation and share insights into the scientific, operational, and strategic challenges that shape early-stage healthcare investing.
Areas of Interest
My investment interests span therapeutics, medical devices, and selective digital health opportunities, each with distinct risk, development, and commercialization dynamics.
Therapeutics:
I am drawn to therapeutics companies pursuing innovative science with the potential to address significant unmet medical needs.
Given my focus as an early-stage investor, I favor companies with a clear, capital-efficient path to clinical development and early proof of concept.
Medical Devices:
Medical devices often require less capital to develop than therapeutics while delivering equally high impact on patient care.
To balance the typically lower return profile, I look for factors that help derisk the investment, including design freeze, regulatory clarity such as 510(k) pathways, existing reimbursement frameworks, and practical clinical adoption potential.
Digital Health:
Digital health remains an evolving and rapidly changing sector. While long-term value-creation models are still developing across parts of the market, I believe the sector will continue to produce compelling opportunities through innovation and improved integration into healthcare delivery.
I am particularly interested in companies addressing clear clinical or operational challenges with strong workflow integration and practical implementation potential.
Founders I Enjoy Working With
I enjoy working with founders who are deeply passionate about the problems they are trying to solve and driven by a genuine mission to improve healthcare outcomes.
Beyond technical excellence, I value founders who demonstrate self-awareness, strategic thinking, and intellectual honesty. Building healthcare companies is inherently complex, and I appreciate leaders who understand both their strengths and the areas where they need support.
I view investing as a long-term partnership rather than a transactional relationship. I am drawn to founders who are open to feedback, willing to engage in thoughtful discussions, and interested in building enduring relationships with their investors and advisors.
Trust and transparency are especially important to me. I respect founders who communicate openly — especially when challenges arise. Early-stage healthcare innovation inevitably involves uncertainty, and honest communication is essential for navigating it effectively.
Above all, I value founders who combine ambition, integrity, intellectual curiosity, and commitment to building enduring products with long-term health impact.